BPC-157

BPC-157, also called Body Protection Compound-157, is a synthetic peptide composed of 15 amino acids (sequence GEPPPGKPADDAGLV) initially discovered in human gastric juice proteins BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers+1. It originated from a screening program at the University of Zagreb in the 1990s, where it was labeled as candidate number 157 BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Research has primarily investigated its potential to accelerate the repair of soft tissues such as tendons, ligaments, and skeletal muscle, as well as to protect the gastrointestinal lining Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review+1. While a large body of preclinical work shows consistent healing effects across animal models, human evidence remains limited to small uncontrolled studies and a single two-subject safety pilot Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review+2. The compound's unusual stability in gastric fluid and its impact on blood vessel and connective tissue repair pathways have made it a focus of ongoing interest, though its regulatory approval and clinical validation are still lacking BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers+1.

BPC-157 supports healing by activating blood vessel growth (angiogenesis) and protecting the cells that line blood vessels (endothelial cells) Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery+1. In human artery samples studied in the laboratory, BPC-157 caused the vessel to relax, an effect that depended on intact endothelial cells and nitric oxide signaling Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Animal studies show that after injury, BPC-157 reduces oxidative stress and cell death while increasing factors that stimulate new vessel formation, such as VEGF Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury+1. It also appears to activate fibroblasts, the cells that produce connective tissue, and to sensitize cells to growth hormone by increasing growth hormone receptors, which may amplify repair signals Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. While these mechanisms are well-supported in animal and cell studies, direct confirmation in human injured tissue is not yet available.

In animal models, BPC-157 has consistently improved the healing of tendons, ligaments, and muscle, with histological and mechanical tests showing stronger, more organized repair tissue Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review+1. It has also shown protective effects in gastrointestinal injury models, reducing ulcer formation and aiding mucosal recovery Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. In studies of ischemia-reperfusion injury — when tissue is damaged after blood flow returns — BPC-157 reduced oxidative stress and cell death in multiple organs including muscle, liver, and brain Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury+2. The limited human data suggest possible symptom relief for chronic knee pain and interstitial cystitis, but these were small, uncontrolled trials, so the effects are not yet confirmed Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study+1. Overall, the documented effects point to a broad pro-healing influence, but human evidence remains at an early stage.

Animal research protocols for BPC-157 often use doses in the microgram-per-kilogram range, such as 20 μg/kg given by intraperitoneal injection in ischemia-reperfusion models Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Human studies have been limited: a bladder pain pilot used a single 10 mg injection directly into the bladder Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study, and a knee pain study involved unspecified intra-articular doses Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Community protocols, which are not validated by clinical trials, typically involve 200-500 mcg subcutaneously once or twice daily for 2-6 weeks, depending on the injury severity. The short plasma half-life of under 30 minutes suggests that more frequent dosing may be needed, but because biological effects appear to persist after the peptide clears, optimal dosing schedules are not established Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs+1. The interactive timeline card above shows one common research-based pattern.

BPC-157 is typically supplied as a lyophilized powder that must be reconstituted before use. Bacteriostatic water is the recommended diluent for multi-dose vials; sterile water can be used for single-dose preparations BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. To reconstitute, gently inject the diluent down the vial wall, then swirl slowly until the solution is clear — vigorous shaking can damage the peptide. After reconstitution, the solution should be stored in the refrigerator at 2-8°C and used within 14-30 days if bacteriostatic water was used, or within 24-72 hours with sterile water. Unreconstituted vials can be stored refrigerated or frozen for longer periods, protected from moisture and temperature swings. Because precise dosing requires careful measurement, an interactive calculator is provided on this page to help determine volumes.

No formal human drug-interaction studies have been conducted with BPC-157. Because it relaxes blood vessels through nitric oxide pathways, it could theoretically have additive effects when combined with blood pressure medications, nitrates, or drugs for erectile dysfunction like sildenafil BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers+1. Animal research suggests BPC-157 may influence clotting and bleeding in complex ways, so caution is warranted with anticoagulants or antiplatelet drugs, particularly near surgery Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. It does not appear to interact directly with anti-inflammatory medications, but animal studies indicate it might counteract some of the tissue-damaging effects of NSAIDs and corticosteroids Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery+1. Given the lack of data, any combination should be approached with caution, and monitoring for blood pressure changes or unusual bleeding is advised.

Most community protocols incorporate cycling — periods of use followed by breaks — because the long-term safety of continuous BPC-157 exposure is unknown BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. A typical cycle lasts 2-6 weeks, followed by a rest period of 1-4 weeks before reassessing. The rationale includes the peptide's short half-life (under 30 minutes), which means it clears quickly, yet its biological effects on tissue repair can outlast the drug's presence Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs+1. Cycling also aims to reduce any potential risks of prolonged pro-angiogenic signaling, though no evidence indicates that this is harmful Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Signs that a break may be needed include reaching functional healing, plateau in improvement, or new side effects like edema or palpitations. Because there are no human trials defining optimal cycle lengths, these patterns are based on practical experience rather than controlled data.

BPC-157 is frequently combined with other research peptides, particularly TB-500 (thymosin beta-4), based on the idea that their mechanisms — angiogenesis and cell migration — may complement each other Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Human evidence for this stack is minimal: one small knee-pain study included patients who received both, but the study was uncontrolled and could not isolate the effects Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Stacks with growth hormone secretagogues like CJC-1295 or ipamorelin are also common in practice, but no published studies have tested their combined effects, and they may increase the difficulty of identifying which compound is responsible for side effects such as swelling or glucose changes. Any stacking should start with single compounds first to assess individual response before adding others.

BPC-157 is not approved by the U.S. Food and Drug Administration (FDA) for any medical condition, and it lacks authorization from any major international regulatory agency BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. In the U.S., it is considered an investigational compound, and its eligibility for pharmacy compounding has been under FDA review BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. The World Anti-Doping Agency (WADA) lists it as a prohibited substance under the category of unapproved agents, meaning athletes are at risk of sanctions if it is detected BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers+1. Practical availability persists through nonstandard channels, but this comes with unknown product quality and legal risk. For those in sport, the safest course is to avoid it entirely until further notice.

Human safety data for BPC-157 are extremely limited. A pilot study that gave up to 20 mg intravenously to two people reported no adverse effects, but this provides little reassurance about rare or long-term risks Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. In animal toxicology, BPC-157 has shown low acute toxicity BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers+1. Theoretical concerns focus on its ability to stimulate new blood vessel growth: while this may aid healing, it could potentially support tumor growth or affect vascular stability in unanticipated ways Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review+1. Other practical risks include product contamination from unregulated suppliers, dosing errors, and injection-site reactions Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. No studies have established safety during pregnancy, breastfeeding, or in people with cancer, so these groups should avoid use.